bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Linking Physical Activity to Breast Cancer Risk via Inflammation, Part 1: The Effect of Physical Activity on Inflammation
Authors: Swain Christopher T.V. , Drummond Ann E. , Milne Roger L. , English Dallas R. , Brown Kristy A. , Lou Makayla W.C. , Boing Leonessa , Bageley Amy , Skinner Tina L. , van Roekel Eline H. , Moore Melissa M. , Gaunt Tom R. , Martin Richard M. , Lewis Sarah J. , Lynch Brigid M.
Published: April 2023

Abstract
The protective effect of physical activity on breast cancer incidence may partially be mediated by inflammation. Systematic searches of Medline, EMBASE, and SPORTDiscus were performed to identify intervention studies, Mendelian randomization studies, and prospective cohort studies that examined the effects of physical activity on circulating inflammatory biomarkers in adult women. Meta-analyses were performed to generate effect estimates. Risk of bias was assessed, and the Grading of Recommendations Assessment, Development, and Evaluation system was used to determine the overall quality of the evidence. Thirty-five intervention studies and one observational study met the criteria for inclusion. Meta-analyses of randomized controlled trials (RCT) indicated that, compared with control groups, exercise interventions reduced levels of C-reactive protein (CRP) [standardized mean difference (SMD) = −0.27, 95% confidence interval (CI) = −0.62 to 0.08), tumor necrosis factor alpha (TNFα, SMD = −0.63, 95% CI = −1.04 to −0.22), interleukin-6 (IL6, SMD = −0.55, 95% CI = −0.97 to −0.13) and leptin (SMD = −0.50, 95% CI = −1.10 to 0.09). Owing to heterogeneity in effect estimates and imprecision, evidence strength was graded as low (CRP, leptin) or moderate (TNFα and IL6). High-quality evidence indicated that exercise did not change adiponectin levels (SMD = 0.01, 95% CI = −0.14 to 0.17). These findings provide support for the biological plausibility of the first part of the physical activity—inflammation—breast cancer pathway.
Supplementary Figures Legends from A Novel Compound, NK150460, Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor
Authors: Fukasawa Kazuteru , Kagaya Shigehide , Maruyama Sakiko , Kuroiwa Shunsuke , Masuda Kuniko , Kameyama Yoshio , Satoh Yoshitaka , Akatsu Yuichi , Tomura Arihiro , Nishikawa Kiyohiro , Horie Shigeo , Ichikawa Yuh-ichiro
Published: April 2023

Supplementary Figures Legends. Legends for Supplementary Figures
Supplementary Figure 6 from A Novel Compound, NK150460, Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor
Authors: Fukasawa Kazuteru , Kagaya Shigehide , Maruyama Sakiko , Kuroiwa Shunsuke , Masuda Kuniko , Kameyama Yoshio , Satoh Yoshitaka , Akatsu Yuichi , Tomura Arihiro , Nishikawa Kiyohiro , Horie Shigeo , Ichikawa Yuh-ichiro
Published: April 2023

Supplementary Figure 6. The calculated chemical shifts of NK150460 and M-2 by NMR.
Figure S5 from A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non–Small Cell Lung Cancer Cell Lines
Authors: Zubovych Iryna O. , Sethi Anirudh , Kulkarni Aditya , Tagal Vural , Roth Michael G.
Published: April 2023

Figure S5. SW044248 induces eIF2a phosphorylation in sensitive cells, SW202742 does not.
Supplementary Video 1 from A Murine Model for Quantitative, Real-Time Evaluation of Convection-Enhanced Delivery (RT-CED) Using an 18[F]-Positron Emitting, Fluorescent Derivative of Dasatinib
Authors: Wang Melinda , Kommidi Harikrishna , Tosi Umberto , Guo Hua , Zhou Zhiping , Schweitzer Melanie E. , Wu Linda Y. , Singh Ranjodh , Hou Shengqi , Law Benedict , Ting Richard , Souweidane Mark M.
Published: April 2023

Data was not quantitated due to mouse movement at 2 hours. (mouse began to wake from isoflurane anesthesia)
Supplementary Table Legends from Inhibition of Nucleotide Synthesis Targets Brain Tumor Stem Cells in a Subset of Glioblastoma
Authors: Laks Dan R. , Ta Lisa , Crisman Thomas J. , Gao Fuying , Coppola Giovanni , Radu Caius G. , Nathanson David A. , Kornblum Harley I.
Published: April 2023

Table legend for supplementary Table 1.
Supplementary Table 2 from Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma
Authors: Ohata Yoshiteru , Shimada Shu , Akiyama Yoshimitsu , Mogushi Kaoru , Nakao Keisuke , Matsumura Satoshi , Aihara Arihiro , Mitsunori Yusuke , Ban Daisuke , Ochiai Takanori , Kudo Atsushi , Arii Shigeki , Tanabe Minoru , Tanaka Shinji
Published: April 2023

Genes commonly upregulated in HuH7-F6 and -F12 cells compared with HuH7-F0
Supplementary Figure Legend from Small-Molecule IAP Antagonists Sensitize Cancer Cells to TRAIL-Induced Apoptosis: Roles of XIAP and cIAPs
Authors: Finlay Darren , Vamos Mitchell , González-López Marcos , Ardecky Robert J. , Ganji Santhi Reddy , Yuan Hongbin , Su Ying , Cooley Trina R. , Hauser Curt T. , Welsh Kate , Reed John C. , Cosford Nicholas D.P. , Vuori Kristiina
Published: April 2023

PDF - 53KB, Legend for Supplementary Figure 1.
Supplementary Methods from SC-60, a Dimer-Based Sorafenib Derivative, Shows a Better Anti–Hepatocellular Carcinoma Effect than Sorafenib in a Preclinical Hepatocellular Carcinoma Model
Authors: Tai Wei-Tien , Shiau Chung-Wai , Li Yong-Shi , Chen Yao-Li , Chu Pei-Yi , Huang Jui-Wen , Hsu Cheng-Yi , Hsu Yi-Chieh , Chen Pei-Jer , Chen Kuen-Feng
Published: April 2023

PDF - 172K, Supplementary Methods
Supplementary Figure 2: Dinaciclib induces S-phase accumulation and reduces G2/M-phase accumulation from A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition
Authors: Alagpulinsa David A. , Ayyadevara Srinivas , Yaccoby Shmuel , Shmookler Reis Robert J.
Published: April 2023

(A, B) H929 cells were treated as indicated for 24 h and cell-cycle distribution assessed by propidium iodide (PI) staining as described in Figure 5.
Table S2 from Receptor Tyrosine Kinase Phosphorylation Pattern–Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment
Authors: Sun Xiaoxiao , Song Qiaoling , He Li , Yan Lei , Liu Jingli , Zhang Qing , Yu Qiang
Published: April 2023

Analysis of RTK arrays in literature (cancer cell lines).
Table S1 from Receptor Tyrosine Kinase Phosphorylation Pattern–Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment
Authors: Sun Xiaoxiao , Song Qiaoling , He Li , Yan Lei , Liu Jingli , Zhang Qing , Yu Qiang
Published: April 2023

Sensitivities of the cancer cells to single RTKi treatment.
Supplementary Figure S6 from EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes
Authors: Hernando Henar , Gelato Kathy A. , Lesche Ralf , Beckmann Georg , Koehr Silke , Otto Saskia , Steigemann Patrick , Stresemann Carlo
Published: April 2023

Effect of E7438 on body weight of MOLP-8 xenograft mice
Figure S4 from Receptor Tyrosine Kinase Phosphorylation Pattern–Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment
Authors: Sun Xiaoxiao , Song Qiaoling , He Li , Yan Lei , Liu Jingli , Zhang Qing , Yu Qiang
Published: April 2023

Dual inhibition of Erk and Akt phosphorylation and reduction of c-Myc protein level were essential for the RTKi combinations to block cancer cell growth.
Supplementary Figure S2 from EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes
Authors: Hernando Henar , Gelato Kathy A. , Lesche Ralf , Beckmann Georg , Koehr Silke , Otto Saskia , Steigemann Patrick , Stresemann Carlo
Published: April 2023

Effects of E7438 treatment in MM cell lines
Supplementary Figure 1 from Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors
Authors: Mazarico José M. , Sánchez-Arévalo Lobo Victor J. , Favicchio Rosy , Greenhalf William , Costello Eithne , Carrillo-de Santa Pau Enrique , Marqués Miriam , Lacal Juan C. , Aboagye Eric , Real Francisco X.
Published: April 2023

Analysis of antibody specifity
Supplementary Table 2 from In Vitro and In Vivo Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers
Authors: Altwerger Gary , Bonazzoli Elena , Bellone Stefania , Egawa-Takata Tomomi , Menderes Gulden , Pettinella Francesca , Bianchi Anna , Riccio Francesco , Feinberg Jacqueline , Zammataro Luca , Han Chanhee , Yadav Ghanshyam , Dugan Katherine , Morneault Ashley , Ponte Jose F. , Buza Natalia , Hui Pei , Wong Serena , Litkouhi Babak , Ratner Elena , Silasi Dan-Arin , Huang Gloria S. , Azodi Masoud , Schwartz Peter E. , Santin Alessandro D.
Published: April 2023

SUPPLEMENTAL Table 2: Uterine serous cell lines with demographics, stage, histologic grade, primary site of tumor, Mean fluorescence intensity (MFI) and score for FRα (folic acid alpha receptor).
Supplementary Figure 3 from In Vitro and In Vivo Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers
Authors: Altwerger Gary , Bonazzoli Elena , Bellone Stefania , Egawa-Takata Tomomi , Menderes Gulden , Pettinella Francesca , Bianchi Anna , Riccio Francesco , Feinberg Jacqueline , Zammataro Luca , Han Chanhee , Yadav Ghanshyam , Dugan Katherine , Morneault Ashley , Ponte Jose F. , Buza Natalia , Hui Pei , Wong Serena , Litkouhi Babak , Ratner Elena , Silasi Dan-Arin , Huang Gloria S. , Azodi Masoud , Schwartz Peter E. , Santin Alessandro D.
Published: April 2023

Determination by ICso of IMGN853 cytotoxicity compared to controls, ADC isotype and M9346A, in primary USC cell lines (ie, END(K) 149 and ARK19) with 2+ FRα expression
Supplementary Figure 1 from In Vitro and In Vivo Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers
Authors: Altwerger Gary , Bonazzoli Elena , Bellone Stefania , Egawa-Takata Tomomi , Menderes Gulden , Pettinella Francesca , Bianchi Anna , Riccio Francesco , Feinberg Jacqueline , Zammataro Luca , Han Chanhee , Yadav Ghanshyam , Dugan Katherine , Morneault Ashley , Ponte Jose F. , Buza Natalia , Hui Pei , Wong Serena , Litkouhi Babak , Ratner Elena , Silasi Dan-Arin , Huang Gloria S. , Azodi Masoud , Schwartz Peter E. , Santin Alessandro D.
Published: April 2023

Immunohistochemistry (IHC) showing expression of FRα endometrioid cancer cell blocks
Supplementary Data from The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors
Authors: Wang Xinyi , Ai Jing , Liu Hongyan , Peng Xia , Chen Hui , Chen Yi , Su Yi , Shen Aijun , Huang Xun , Ding Jian , Geng Meiyu
Published: April 2023

Table S1. Lists of antibodies, small interference RNA sequences and inhibitors used in this study
Supplemental Figures S1-S13 and Tables S1-S3 from Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer
Authors: Hata Tsuyoshi , Rajabi Hasan , Yamamoto Masaaki , Jin Caining , Ahmad Rehan , Zhang Yan , Kui Ling , Li Wei , Yasumizu Yota , Hong Deli , Miyo Masaaki , Hiraki Masayuki , Maeda Takahiro , Suzuki Yozo , Takahashi Hidekazu , Samur Mehmet , Kufe Donald
Published: April 2023

Supplemental Figure S1. Targeting NF-kappaB p65 has little effect on TWIST1 expression; Supplemental Figure S2. Targeting MUC1-C is not associated with regulation of STAT3 mRNA levels; Supplemental Figure S3. Targeting STAT3 genetically or pharmacologically decreases TWIST1 expression; Supplemental Figure S4. MUC1-C and STAT3 form a nuclear complex; Supplemental Figure S5. Hallmark pathway analysis for BT-549 cells; Supplemental Figure 6. Hallmark pathway analysis for SUM149 cells; Supplemental Figure S7. Metacore adherens junction disassembly and EMT pathway analysis for BT-549 cells; Supplemental Figure S8. Metacore EMT pathway analysis for SUM149 cells; Supplemental Figure S9. Silencing MUC1-C inhibits cell invasive capacity; Supplemental Figure S10. Silencing MUC1-C inhibits growth of BT-549 and SUM149 cells; Supplemental Figure S11. Silencing MUC1-C inhibits colony formation of SUM149 cells; Supplemental Figure S12. Downregulation of MUC1-C and TWIST1 expression in vivo; Supplemental Figure S13. Selection of BT-549 cells for PTX resistance; Supplemental Table S1: Primers sequences for qRT-PCR; Supplemental Table S2: Primers used in ChIP assays; Supplemental Table S3: Combination FA and CI values.
Supplemental information, tables, and figures from Targeting Notch1 and IKKα Enhanced NF-κB Activation in CD133+ Skin Cancer Stem Cells
Authors: Quan Xin Xin , Hawk Nga Voong , Chen Weiping , Coupar Jamie , Lee Steven K. , Petersen David W. , Meltzer Paul S. , Montemarano Andrew , Braun Martin , Chen Zhong , Van Waes Carter
Published: April 2023

1. Supplementary Methods. 2. References. 3. Supplementary Table 1. Characteristics of human primary SCC samples. 4. Supplementary Table 2. Clinical characteristics of tumor samples used in different experimental platforms. 5. Supplemental Table 3. GeneGo analysis summery of top 10 ranked signaling pathways for the stem gene signature of CD133+ hcSCC cancer stem cells. 6. Supplementary Figure 1. Clinical information of human primary cutaneous SCC samples and schematic strategy for isolation of cancer stem cell population and function assays. 7. Supplementary Figure 2. Characteristics of transcriptional profile and the top pathways of differentially expressed genes in CD133+ CSCs population. 8. Supplementary Figure 3. IKKα co-localized with CD133 expression in cSCC tissues.
Supplementary Data from GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression
Authors: Cucchiara Vito , Yang Joy C. , Liu Chengfei , Adomat Hans H. , Tomlinson Guns Emma S. , Gleave Martin E. , Gao Allen C. , Evans Christopher P.
Published: April 2023

Suppl. Figure1. Western blots of AR-FL and AR-V7 of A. CWR22Rv1 B. VCaP cells treated with leuprolide or degarelix. Suppl. Figure 2. Western blots of AR-V7 in representative tumor lysates from control, castration, leuprolide and degarelix groups.
Figure S1 from TRAF2 Cooperates with Focal Adhesion Signaling to Regulate Cancer Cell Susceptibility to Anoikis
Authors: da Silva Sabrina Daniela , Xu Bin , Maschietto Mariana , Marchi Fabio Albuquerque , Alkailani Maisa I. , Bijian Krikor , Xiao Dingzhang , Alaoui-Jamali Moulay A.
Published: April 2023

Schematic representation of protein-protein interaction network.
Supplementary Figure S2 from Leelamine Is a Novel Lipogenesis Inhibitor in Prostate Cancer Cells In Vitro and In Vivo
Authors: Singh Krishna B. , Hahm Eun-Ryeong , Pore Subrata K. , Singh Shivendra V.
Published: April 2023

Effect of leelamine treatment on histology and wet weight of vital organs.
Figure S5 from HSP90 Inhibitor–SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors
Authors: Proia David A. , Smith Donald L. , Zhang Junyi , Jimenez John-Paul , Sang Jim , Ogawa Luisa Shin , Sequeira Manuel , Acquaviva Jaime , He Suqin , Zhang Chaohua , Khazak Vladimir , Astsaturov Igor , Inoue Takayo , Tatsuta Noriaki , Osman Sami , Bates Richard C. , Chimmanamada Dinesh , Ying Weiwen
Published: April 2023

Body weights.
Supplementary Data from The Existence of MTH1-independent 8-oxodGTPase Activity in Cancer Cells as a Compensatory Mechanism against On-target Effects of MTH1 Inhibitors
Authors: Samaranayake Govindi J. , Troccoli Clara I. , Zhang Ling , Huynh Mai , Jayaraj Christina J. , Ji Debin , McPherson Lisa , Onishi Yoshiyuki , Nguyen Dao M. , Robbins David J. , Karbaschi Mahsa , Cooke Marcus S. , Barrientos Antonio , Kool Eric T. , Rai Priyamvada
Published: April 2023

Supplementary legends and figures
Table S3 from Monoclonal Antibody Targeting Sialyl-di-Lewisa–Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential
Authors: Tivadar Silvana T. , McIntosh Richard S. , Chua Jia Xin , Moss Robert , Parsons Tina , Zaitoun Abed M. , Madhusudan Srinivasan , Durrant Lindy G. , Vankemmelbeke Mireille
Published: April 2023

Comparison of FG129 and CA19.9 mAb SPM110 binding (both at 7.4 nmol/L) to a panel of normal human tissues (AMSBIO TMA)
Figure S3 from Monoclonal Antibody Targeting Sialyl-di-Lewisa–Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential
Authors: Tivadar Silvana T. , McIntosh Richard S. , Chua Jia Xin , Moss Robert , Parsons Tina , Zaitoun Abed M. , Madhusudan Srinivasan , Durrant Lindy G. , Vankemmelbeke Mireille
Published: April 2023

Limited normal human tissue distribution of FG129 glyco-epitope
Figure S2 from Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
Authors: Mao Fengyi , Li Jie , Luo Qian , Wang Ruixin , Kong Yifan , Carlock Colin , Liu Zian , Elzey Bennet D. , Liu Xiaoqi
Published: April 2023

PD-L1 expression level of three cell lines
Supplementary Fig. S6 from A Multifunctional Therapy Approach for Cancer: Targeting Raf1- Mediated Inhibition of Cell Motility, Growth, and Interaction with the Microenvironment
Authors: Zhang Limin , Pattanayak Abhinandan , Li Wenqi , Ko Hyun-Kyung , Fowler Graham , Gordon Ryan , Bergan Raymond
Published: April 2023

Supplementary Fig. S6 shows weekly IVIS signals in mice bearing human prostate cancer and treated with zoledronic acid and/or KBU2046
Supplemental Table 1 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor
Authors: Lemberg Kathryn M. , Zhao Liang , Wu Ying , Veeravalli Vijayabhaskar , Alt Jesse , Aguilar Joanna Marie H. , Dash Ranjeet P. , Lam Jenny , Tenora Lukáš , Rodriguez Chabely , Nedelcovych Michael T. , Brayton Cory , Majer Pavel , Blakeley Jaishri O. , Rais Rana , Slusher Barbara S.
Published: April 2023

Supplemental Table 1: List of significantly affected metabolites identified in volcano plot following JHU395 versus vehicle treatment of flank MPNST
Supplemental Figure 5 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor
Authors: Lemberg Kathryn M. , Zhao Liang , Wu Ying , Veeravalli Vijayabhaskar , Alt Jesse , Aguilar Joanna Marie H. , Dash Ranjeet P. , Lam Jenny , Tenora Lukáš , Rodriguez Chabely , Nedelcovych Michael T. , Brayton Cory , Majer Pavel , Blakeley Jaishri O. , Rais Rana , Slusher Barbara S.
Published: April 2023

Supplemental Figure 5: 13C5-glutamine in vivo flux analysis in vehicle vs JHU395 treated tumors
Supplementary Fig. S4` from A Multifunctional Therapy Approach for Cancer: Targeting Raf1- Mediated Inhibition of Cell Motility, Growth, and Interaction with the Microenvironment
Authors: Zhang Limin , Pattanayak Abhinandan , Li Wenqi , Ko Hyun-Kyung , Fowler Graham , Gordon Ryan , Bergan Raymond
Published: April 2023

Supplementary Fig. S4 shows that KBU2046 inhibits Raf1 signaling in osteoclasts
Supplemental Figure 2 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor
Authors: Lemberg Kathryn M. , Zhao Liang , Wu Ying , Veeravalli Vijayabhaskar , Alt Jesse , Aguilar Joanna Marie H. , Dash Ranjeet P. , Lam Jenny , Tenora Lukáš , Rodriguez Chabely , Nedelcovych Michael T. , Brayton Cory , Majer Pavel , Blakeley Jaishri O. , Rais Rana , Slusher Barbara S.
Published: April 2023

Supplemental Figure 2: JHU395 DON delivery to P493B lymphoma cells and in vivo time-dependent pharmacokinetics of JHU395 in CD-1 mouse plasma and jejunum
Supplementary Table S4 from MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
Authors: Merlino Giuseppe , Fiascarelli Alessio , Bigioni Mario , Bressan Alessandro , Carrisi Corrado , Bellarosa Daniela , Salerno Massimiliano , Bugianesi Rossana , Manno Rosanna , Bernadó Morales Cristina , Arribas Joaquin , Bisht Arnima , Kaplan Angelo , Boyd Robert , Do Uyen T. , Swaminathan Sudha , Attanasio Nickolas , Lou San Lin , Dusek Rachel L. , Ackroyd James E. , Pham Phuoc Huy , Awdew Rahel , Aud Dee , Trang Michael , Lynch Carmel M. , Terrett Jonathan , Wilson Keith E. , Rohlff Christian , Manzini Stefano , Pellacani Andrea , Binaschi Monica
Published: April 2023

Supplementary Table S4: Antitumor activity of MEN1309/OBT076 on xenograft and PDX models with different CD205 antigen expression. a) PDX models.b) Score indicate the staining intensity. HE = heterogeneous. HO = homogeneous. c) TVI%, tumor volume inhibition, expressed as a percentage, indicates the ratio % between the mean of the tumor volume of the test article-treated group and the control treated with drug vehicle calculated at the Nadir of tumor growth.
Supplementary S3 A-B from MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
Authors: Merlino Giuseppe , Fiascarelli Alessio , Bigioni Mario , Bressan Alessandro , Carrisi Corrado , Bellarosa Daniela , Salerno Massimiliano , Bugianesi Rossana , Manno Rosanna , Bernadó Morales Cristina , Arribas Joaquin , Bisht Arnima , Kaplan Angelo , Boyd Robert , Do Uyen T. , Swaminathan Sudha , Attanasio Nickolas , Lou San Lin , Dusek Rachel L. , Ackroyd James E. , Pham Phuoc Huy , Awdew Rahel , Aud Dee , Trang Michael , Lynch Carmel M. , Terrett Jonathan , Wilson Keith E. , Rohlff Christian , Manzini Stefano , Pellacani Andrea , Binaschi Monica
Published: April 2023

Supplementary Figure S3-A. Representative image of IHC staining for CD205 in a tumor mass from HCC-70 xenograft model, 16 days far from the initial treatment with 5 mg/kg of MEN1309/OBT076. The semiquantitative IHC analysis showed a score of 1+ in 30% of cells while the remaining were scored negative (0). Supplementary Figure S3-B. Representative image of IHC staining for CD205 in a tumor mass from PDX-347 model, 16 days far from the initial treatment with 5 mg/kg of MEN1309/OBT076. The semiquantitative IHC analysis showed a score of 2+ in 100% of cells. Red and green lines represent tumor and fibrotic areas.
Supplementary Table 2 from Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages
Authors: Iwanowycz Stephen , Wang Junfeng , Hodge Johnie , Wang Yuzhen , Yu Fang , Fan Daping
Published: April 2023

Primers used for ChIP assays
Supplementary Table 5 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Authors: Villar-Prados Alejandro , Wu Sherry Y. , Court Karem A. , Ma Shaolin , LaFargue Christopher , Chowdhury Mamur A. , Engelhardt Margaret I. , Ivan Cristina , Ram Prahlad T. , Wang Ying , Baggerly Keith , Rodriguez-Aguayo Cristian , Lopez-Berestein Gabriel , Yang Shyh-Ming , Maloney David J. , Yoshioka Makoto , Strovel Jeffrey W. , Roszik Jason , Sood Anil K.
Published: April 2023

Raw RPPA data for OVCAR 5.
Supplementary Figure 4 from Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages
Authors: Iwanowycz Stephen , Wang Junfeng , Hodge Johnie , Wang Yuzhen , Yu Fang , Fan Daping
Published: April 2023

Emodin has little effect on tumor cell proliferation and adhesion
Supplementary Table S3 from RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
Authors: Brünker Peter , Wartha Katharina , Friess Thomas , Grau-Richards Sandra , Waldhauer Inja , Koller Claudia Ferrara , Weiser Barbara , Majety Meher , Runza Valeria , Niu Huifeng , Packman Kathryn , Feng Ningping , Daouti Sherif , Hosse Ralf J. , Mössner Ekkehard , Weber Thomas G. , Herting Frank , Scheuer Werner , Sade Hadassah , Shao Cuiying , Liu Bin , Wang Peng , Xu Gary , Vega-Harring Suzana , Klein Christian , Bosslet Klaus , Umaña Pablo
Published: April 2023

FAP-drozitumab antibody-mediated apoptosis does not correlate with DR5.
Supplementary Figure S3 from RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
Authors: Brünker Peter , Wartha Katharina , Friess Thomas , Grau-Richards Sandra , Waldhauer Inja , Koller Claudia Ferrara , Weiser Barbara , Majety Meher , Runza Valeria , Niu Huifeng , Packman Kathryn , Feng Ningping , Daouti Sherif , Hosse Ralf J. , Mössner Ekkehard , Weber Thomas G. , Herting Frank , Scheuer Werner , Sade Hadassah , Shao Cuiying , Liu Bin , Wang Peng , Xu Gary , Vega-Harring Suzana , Klein Christian , Bosslet Klaus , Umaña Pablo
Published: April 2023

Characterization and optimization of RG7386 dosing in vivo.
Supplementary Figure S2 and Table S4 from RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
Authors: Brünker Peter , Wartha Katharina , Friess Thomas , Grau-Richards Sandra , Waldhauer Inja , Koller Claudia Ferrara , Weiser Barbara , Majety Meher , Runza Valeria , Niu Huifeng , Packman Kathryn , Feng Ningping , Daouti Sherif , Hosse Ralf J. , Mössner Ekkehard , Weber Thomas G. , Herting Frank , Scheuer Werner , Sade Hadassah , Shao Cuiying , Liu Bin , Wang Peng , Xu Gary , Vega-Harring Suzana , Klein Christian , Bosslet Klaus , Umaña Pablo
Published: April 2023

Figure S2. Related to Figure 3. In vitro characterization of the FAP-DR5 BsAb RG7386; Table S4. Characterization of RG7386 binding avidities.
Supplementary Figures S1-S7 from LGR5-Targeted Antibody–Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence
Authors: Gong Xing , Azhdarinia Ali , Ghosh Sukhen C. , Xiong Wei , An Zhiqiang , Liu Qingyun , Carmon Kendra S.
Published: April 2023

Supplementary Fig. S1- Coomassie gel of anti-LGR5 mAb and anti-LGR5 ADCs. Supplementary Fig. S2- Confocal image of HEK293T cells with stable over-expression of hLGR4. Supplementary Fig. S3- Anti-LGR5 ADC binding assay and cytotoxicity of free MMAE. Supplementary Fig. S4- Anti-LGR5 mAb crossreactivity with mouse LGR5 and images of intestinal organoids treated with anti-LGR5 ADC or free MMAE. Supplementary Fig. S5- Representative images of LoVo xenograft tumors in mice from each treatment cohort and graph of average body weight. Supplementary Fig. S6- H&E staining of intestinal tissue sections. Supplementary Fig. S7. Images of Lovo xenograft tumor recurrence and weight.
Supplementary Figure S1 from Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Authors: Andreev Julian , Thambi Nithya , Perez Bay Andres E. , Delfino Frank , Martin Joel , Kelly Marcus P. , Kirshner Jessica R. , Rafique Ashique , Kunz Arthur , Nittoli Thomas , MacDonald Douglas , Daly Christopher , Olson William , Thurston Gavin
Published: April 2023

Supplementary Figure S1. A, Structure of the PRLR and HER2 ADCs. B, Upon 24h incubation, PRLR, but not HER2 antibody accumulated in low pH vesicles of T47D cells. T47D cells were grown in 96-well optical plates.
Table S4 from TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers
Authors: Zaman Guido J.R. , de Roos Jeroen A.D.M. , Libouban Marion A.A. , Prinsen Martine B.W. , de Man Jos , Buijsman Rogier C. , Uitdehaag Joost C.M.
Published: April 2023

Gene Set Analysis of NTRC 0066-0 response
Table S3 from TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers
Authors: Zaman Guido J.R. , de Roos Jeroen A.D.M. , Libouban Marion A.A. , Prinsen Martine B.W. , de Man Jos , Buijsman Rogier C. , Uitdehaag Joost C.M.
Published: April 2023

Replicate dose-response data in additional cancer cell lines and isogenic cell lines
Figure S3 from TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers
Authors: Zaman Guido J.R. , de Roos Jeroen A.D.M. , Libouban Marion A.A. , Prinsen Martine B.W. , de Man Jos , Buijsman Rogier C. , Uitdehaag Joost C.M.
Published: April 2023

Beta-catenin pathway is activated in CTNNB1 mutant cell lines, and TTK inhibition has no direct regulatory effect on beta-catenin
Figure S1 from TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers
Authors: Zaman Guido J.R. , de Roos Jeroen A.D.M. , Libouban Marion A.A. , Prinsen Martine B.W. , de Man Jos , Buijsman Rogier C. , Uitdehaag Joost C.M.
Published: April 2023

Chemical structures of TTK inhibitors
Supplementary Information from 6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells
Authors: Levrier Claire , Sadowski Martin C. , Rockstroh Anja , Gabrielli Brian , Kavallaris Maria , Lehman Melanie , Davis Rohan A. , Nelson Colleen C.
Published: April 2023

Supplementary Figures S1â^'S9 and figures legends Supplementary Tables S1â^'S6 Supplementary Videos S1â^'S5 and legends
supplementary figure legends from Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non–Small Cell Lung Cancer
Authors: Feng Jianguo , Zhang Shirong , Wu Kan , Wang Bing , Wong Jeffrey Y.C. , Jiang Hong , Xu Rujun , Ying Lisha , Huang Haixiu , Zheng Xiaoliang , Chen Xufeng , Ma Shenglin
Published: April 2023

supplementary figure legends
Supplementary information from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
Authors: Pradel Leon P. , Ooi Chia-Huey , Romagnoli Solange , Cannarile Michael A. , Sade Hadassah , Rüttinger Dominik , Ries Carola H.
Published: April 2023

Additional details on primary human and cynomolgus material handling, RNA and DNA based assay design as well as SPR experimentation setup
Supplementary figure S3 from Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non–Small Cell Lung Cancer
Authors: Feng Jianguo , Zhang Shirong , Wu Kan , Wang Bing , Wong Jeffrey Y.C. , Jiang Hong , Xu Rujun , Ying Lisha , Huang Haixiu , Zheng Xiaoliang , Chen Xufeng , Ma Shenglin
Published: April 2023

Median effect analysis showing effect of SAHA on cisplatin induced synergistic radiosensitization in A549 cells
Figure S5 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
Authors: Pradel Leon P. , Ooi Chia-Huey , Romagnoli Solange , Cannarile Michael A. , Sade Hadassah , Rüttinger Dominik , Ries Carola H.
Published: April 2023

In situ and in silico analysis of CD206 versus CD163 or IL-4 expression in normal and cancer tissue
Figure S4 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
Authors: Pradel Leon P. , Ooi Chia-Huey , Romagnoli Solange , Cannarile Michael A. , Sade Hadassah , Rüttinger Dominik , Ries Carola H.
Published: April 2023

Gene expression profiling of in vitro differentiated MÏ† for a selection of cytokine receptors
Supplementary figure S1 from Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non–Small Cell Lung Cancer
Authors: Feng Jianguo , Zhang Shirong , Wu Kan , Wang Bing , Wong Jeffrey Y.C. , Jiang Hong , Xu Rujun , Ying Lisha , Huang Haixiu , Zheng Xiaoliang , Chen Xufeng , Ma Shenglin
Published: April 2023

Doses and LD50 values determinations for SAHA and Cisplatin in U2OS reporter cells
Figure S1-S10, Table S1, Table S2 from Inhibition of Aurora A and Aurora B Is Required for the Sensitivity of HPV-Driven Cervical Cancers to Aurora Kinase Inhibitors
Authors: Martin David , Fallaha Sora , Proctor Martina , Stevenson Alexander , Perrin Lewis , McMillan Nigel , Gabrielli Brian
Published: April 2023

Supplementary Figures 1-10 and Supplementary Tables 1 and 2
Table S2 from Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer
Authors: Papadaki Maria A. , Stoupis Giannis , Theodoropoulos Panayiotis A. , Mavroudis Dimitris , Georgoulias Vassilis , Agelaki Sofia
Published: April 2023

Table S2 shows the associations between the type of chemotherapy and the presence and phenotype of CTCs before and after treatment. Among HER2-positive patients, there was no correlation between the type of therapy and the detection of CTC phenotypes before or after treatment. In the HER2-negative cohort, no associations were observed regarding the baseline detection of distinct CTC subpopulations. Post-treatment, monotherapy with Taxanes or Anthracyclines was strongly associated with negative CTC status (p=0.000) and with absence of CSC+/partial-EMT+ CTCs (p=0.002). In contrast, combination treatment without Taxanes or Anthracyclines resulted in a 100% positivity for CTCs and a higher incidence of CSC+/partial-EMT+ CTCs. All the associations were investigated Exact two-sided Chi-square tests.
Supplementary Information from The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase
Authors: Okada-Iwasaki Ryoko , Takahashi Yuichi , Watanabe Yasuo , Ishida Hiroshi , Saito Jun-ichi , Nakai Ryuichiro , Asai Akira
Published: April 2023

Figure legends of supplementary figure S1-S5
SupplementaryTable S1 from 15α-methoxypuupehenol Induces Antitumor Effects In Vitro and In Vivo against Human Glioblastoma and Breast Cancer Models
Authors: Hilliard Tyvette S. , Miklossy Gabriella , Chock Christopher , Yue Peibin , Williams Philip , Turkson James
Published: April 2023

Supplementary table of the statistical analysis of the TUNEL staining
Supplemental Figure 2: UAB30 increased apoptosis. from Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies
Authors: Waters Alicia M. , Stewart Jerry E. , Atigadda Venkatram R. , Mroczek-Musulman Elizabeth , Muccio Donald D. , Grubbs Clinton J. , Beierle Elizabeth A.
Published: April 2023

Western blotting for caspase 3 was used to detect apoptosis. Whole cell lysates were separated on SDS-PAGE gels and probed with anti-caspase 3 antibody that recognized both total and cleaved products. Total caspase 3 was decreased in all 3 cell lines with UAB30 (100 µM) and cleaved caspase 3 was seen with G401 cells, indicating apoptosis. Staining for β-actin confirmed equal protein loading.
Supplemental Figure 1: UAB30 increased nuclear expression of RXR. from Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies
Authors: Waters Alicia M. , Stewart Jerry E. , Atigadda Venkatram R. , Mroczek-Musulman Elizabeth , Muccio Donald D. , Grubbs Clinton J. , Beierle Elizabeth A.
Published: April 2023

Representative photomicrographs of G401 cells stained for total RXR (red) and nucleus (DAPI, blue) showed increased overlap after UAB30 treatment (merged, bottom right panel) indicating increased RXR staining in the nucleus following UAB30 treatment when compared to control (merged, top right panel).
Supplemental Data from A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis
Authors: Galbán Stefanie , Apfelbaum April A. , Espinoza Carlos , Heist Kevin , Haley Henry , Bedi Karan , Ljungman Mats , Galbán Craig J. , Luker Gary D. , Dort Marcian Van , Ross Brian D.
Published: April 2023

Figure Legends
Figure S2 from A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis
Authors: Galbán Stefanie , Apfelbaum April A. , Espinoza Carlos , Heist Kevin , Haley Henry , Bedi Karan , Ljungman Mats , Galbán Craig J. , Luker Gary D. , Dort Marcian Van , Ross Brian D.
Published: April 2023

Supplemental Figure 2
Supplementary Figures S1-S7; Supplementary Tables S1-S7; and Supplementary Materials and Methods from Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties
Authors: Cao Liangxian , Weetall Marla , Trotta Christopher , Cintron Katherine , Ma Jiyuan , Kim Min Jung , Furia Bansri , Romfo Charles , Graci Jason D. , Li Wencheng , Du Joshua , Sheedy Josephine , Hedrick Jean , Risher Nicole , Yeh Shirley , Qi Hongyan , Arasu Tamil , Hwang Seongwoo , Lennox William , Kong Ronald , Petruska Janet , Moon Young-Choon , Babiak John , Davis Thomas W. , Jacobson Allan , Almstead Neil G. , Branstrom Art , Colacino Joseph M. , Peltz Stuart W.
Published: April 2023

Supplementary Figures S1-S7: Supplementary Figure S1 shows chemical Synthesis and biological characterization of PTC299. Supplementary Figure S2 shows generation and characterization of PTC299-resistant HT1080 cells. Supplementary Figure 3 shows that PTC299 interacts with and inhibits the activity of DHODH. Supplementary Figure S4 shows that PTC299 inhibits de novo UMP production in both sensitive and insensitive cell lines. Supplementary Figure S5 shows that PTC299 has broad activity against leukemia in vitro and in vivo. Supplementary Figure S6 shows

that PTC299 inhibits production of VEGF protein in tumor cells more potently than does brequinar or teriflunomide. 

Supplementary Figure S7 shows the comparison of GSK983 and PTC299 in pharmacokinetic study in mice; Supplementary Tables S1-S7: Supplementary Table S1 shows the information on the source of cells and when they were obtained. Supplementary Table S2 shows that the metabolism of 15N-glutamine in cells treated with PTC299 is similar to that measured in cells treated with brequinar, a known DHODH inhibitor. Supplementary Table S3 shows the summary of enriched proteins identified in PTC299 pull-down samples. Supplementary Table S4 shows PTC299 species selectivity: inhibition of de novo UMP. Supplementary Table S5 shows the preclinical safety profile of PTC299. Supplementary Table S6 shows the demographic information for patients in the NF-2 clinical trial. Supplementary Table S7 shows the differences in expression of genes related to pyrimidine nucleotide synthesis and salvage pathway in hematopoietic cancers versus solid tumors.
Supplementary Excel file-1 from Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties
Authors: Cao Liangxian , Weetall Marla , Trotta Christopher , Cintron Katherine , Ma Jiyuan , Kim Min Jung , Furia Bansri , Romfo Charles , Graci Jason D. , Li Wencheng , Du Joshua , Sheedy Josephine , Hedrick Jean , Risher Nicole , Yeh Shirley , Qi Hongyan , Arasu Tamil , Hwang Seongwoo , Lennox William , Kong Ronald , Petruska Janet , Moon Young-Choon , Babiak John , Davis Thomas W. , Jacobson Allan , Almstead Neil G. , Branstrom Art , Colacino Joseph M. , Peltz Stuart W.
Published: April 2023

contains the raw data from the Microarrays study in the PTC299-resistant HT1080 cells
Figure S3 from Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss–Driven Tumorigenesis
Authors: Cooper Jonathan , Xu Qingwen , Zhou Lu , Pavlovic Milica , Ojeda Virginia , Moulick Kamalika , de Stanchina Elisa , Poirier John T. , Zauderer Marjorie , Rudin Charles M. , Karajannis Matthias A. , Hanemann C. Oliver , Giancotti Filippo G.
Published: April 2023

Figure S3 related to Figure 3 shows that animals maintained weight during the treatments administered in Figure 3.
Figure S1 from Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss–Driven Tumorigenesis
Authors: Cooper Jonathan , Xu Qingwen , Zhou Lu , Pavlovic Milica , Ojeda Virginia , Moulick Kamalika , de Stanchina Elisa , Poirier John T. , Zauderer Marjorie , Rudin Charles M. , Karajannis Matthias A. , Hanemann C. Oliver , Giancotti Filippo G.
Published: April 2023

Figure S1 related to Figure 1 shows that MLN4924 reduces oligo-ubiquitylation of Lats2 and that Merlin-mutant schwannoma cells have a lower on-target sensitivity to MLN4924 than a genetically matched Merlin-positive Schwann line. Also shows that canonical YAP target genes are not expressed highly in FC-1801 cells.
Supplementary Figure S3 from Selective Inhibition of ADAM28 Suppresses Lung Carcinoma Cell Growth and Metastasis
Authors: Mochizuki Satsuki , Shimoda Masayuki , Abe Hitoshi , Miyamae Yuka , Kuramoto Junko , Aramaki-Hattori Noriko , Ishii Ken , Ueno Hideki , Miyakoshi Akira , Kojoh Kanehisa , Okada Yasunori
Published: April 2023

Supplementary Figure S3 shows results of Ki-67-positive cell index of the carcinoma cells within the lung tissue from mice treated with control mouse IgG or antibody 211-14.
Supplementary Data from Selective Inhibition of ADAM28 Suppresses Lung Carcinoma Cell Growth and Metastasis
Authors: Mochizuki Satsuki , Shimoda Masayuki , Abe Hitoshi , Miyamae Yuka , Kuramoto Junko , Aramaki-Hattori Noriko , Ishii Ken , Ueno Hideki , Miyakoshi Akira , Kojoh Kanehisa , Okada Yasunori
Published: April 2023

Description of Supplementary Data
Fig S5 from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
Authors: Benonisson Hreinn , Altıntaş Işıl , Sluijter Marjolein , Verploegen Sandra , Labrijn Aran F. , Schuurhuis Danita H. , Houtkamp Mischa A. , Verbeek J. Sjef , Schuurman Janine , van Hall Thorbald
Published: April 2023

Dynamics of T cell distribution
Table S1 from A Short SOX9 Peptide Mimics SOX9 Tumor Suppressor Activity and Is Sufficient to Inhibit Colon Cancer Cell Growth
Authors: Blache Philippe , Canterel-Thouennon Lucile , Busson Muriel , Verdié Pascal , Subra Gilles , Ychou Marc , Prévostel Corinne
Published: April 2023

Raw data of two series of Scepter measurements. S9pep-DLD-1 cell number, volume and diameter were measured using the ScepterTM Automated Cell Counter at day 11 after doxycycline-induced S9pep expression (+) or not (-). The two independent experiments (light grey and black boxes) show a decrease of cell number and an increase of cell size in CRC cells in which S9pep expression was induced compared with cells without doxycycline.
TableS1, Table S2, Supplementary Methods and Figure Legends from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
Authors: Zhao Genshi , Green Colin F. , Hui Yu-Hua , Prieto Lourdes , Shepard Robert , Dong Sucai , Wang Tao , Tan Bo , Gong Xueqian , Kays Lisa , Johnson Robert L. , Wu Wenjuan , Bhattachar Shobha , Del Prado Miriam , Gillig James R. , Fernandez Maria-Carmen , Roth Ken D. , Buchanan Sean , Kuo Ming-Shang , Geeganage Sandaruwan , Burkholder Timothy P.
Published: April 2023

Table S1: anti-proliferative activity of LSN3154567 against different cancer cell lines; Table S2: effects of NAM on the anti-proliferative activity of LSN3154567
Figure S5 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
Authors: Zhao Genshi , Green Colin F. , Hui Yu-Hua , Prieto Lourdes , Shepard Robert , Dong Sucai , Wang Tao , Tan Bo , Gong Xueqian , Kays Lisa , Johnson Robert L. , Wu Wenjuan , Bhattachar Shobha , Del Prado Miriam , Gillig James R. , Fernandez Maria-Carmen , Roth Ken D. , Buchanan Sean , Kuo Ming-Shang , Geeganage Sandaruwan , Burkholder Timothy P.
Published: April 2023

The concentrations of LSN3154567 in the dog plasma samples.
Figure S1-S2 from COMMD3:BMI1 Fusion and COMMD3 Protein Regulate C-MYC Transcription: Novel Therapeutic Target for Metastatic Prostate Cancer
Authors: Umbreen Syed , Banday Mudassir Meraj , Jamroze Anmbreen , Mansini Adrian P. , Ganaie Arsheed A. , Ferrari Marina G. , Maqbool Raihana , Beigh Firdous H. , Murugan Paari , Morrissey Colm , Corey Eva , Konety Badrinath R. , Saleem Mohammad
Published: April 2023

Supplementary Data showing (i) expression of COMMD3 in PDX models and (ii) association of MYC to COMMD3 in prostate cancer
Figure S1 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
Authors: Zhao Genshi , Green Colin F. , Hui Yu-Hua , Prieto Lourdes , Shepard Robert , Dong Sucai , Wang Tao , Tan Bo , Gong Xueqian , Kays Lisa , Johnson Robert L. , Wu Wenjuan , Bhattachar Shobha , Del Prado Miriam , Gillig James R. , Fernandez Maria-Carmen , Roth Ken D. , Buchanan Sean , Kuo Ming-Shang , Geeganage Sandaruwan , Burkholder Timothy P.
Published: April 2023

Addition of NA rescued the inhibitory activity of LSN3154567.
Supp. Table 3 from Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma
Authors: DeSisto John A. , Flannery Patrick , Lemma Rakeb , Pathak Amrita , Mestnik Shelby , Philips Natalie , Bales Natalie J. , Kashyap Trinayan , Moroze Erin , Venkataraman Sujatha , Kung Andrew L. , Carter Bruce D. , Landesman Yosef , Vibhakar Rajeev , Green Adam L.
Published: April 2023

Summary of p-NF-KB and NF-KB values and ratios from Figure 1f, h and i
Supp. Table 1 from Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma
Authors: DeSisto John A. , Flannery Patrick , Lemma Rakeb , Pathak Amrita , Mestnik Shelby , Philips Natalie , Bales Natalie J. , Kashyap Trinayan , Moroze Erin , Venkataraman Sujatha , Kung Andrew L. , Carter Bruce D. , Landesman Yosef , Vibhakar Rajeev , Green Adam L.
Published: April 2023

Cell line characteristics and selinexor in vitro IC50 levels
Supplementary Methods; Supplementary Figures S1-S6; and Supplementary Tables S1-S4 from Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL
Authors: Bardini Michela , Trentin Luca , Rizzo Francesca , Vieri Margherita , Savino Angela M. , Garrido Castro Patricia , Fazio Grazia , Van Roon Eddy H.J. , Kerstjens Mark , Smithers Nicholas , Prinjha Rab K. , Te Kronnie Geertruy , Basso Giuseppe , Stam Ronald W. , Pieters Rob , Biondi Andrea , Cazzaniga Gianni
Published: April 2023

Supplementary Methods: provide additional information about the methods used in the present study; Supplementary Figure S1: refers to apoptosis analysis of patients-derived xenograft samples exposed to IBET151 ex vivo; Supplementary Figure S2: reports the experimental scheme of patients-derived primary samples xenotransplantations; Supplementary Figure S3: reports the experimental scheme of serial transplantations of residual leukemic cells; Supplementary Figure S4: shows to downregulation of CDK6, c-Myc and Bcl2 induced by I-BET151; Supplementary Figure S5: shows to downregulation of IL7R, CD93, MSI2 and CD72 induced by I-BET151; Supplementary Figure S6: refers to the in vivo imaging analysis of mice treated with DMSO, I-BET151 or IBET151+LBH589 using bioluminescence; Supplementary Table S1: reports the clinical characteristics of the MLL-AF4+ infant ALL patients used in the present study; Supplementary Table S2: reports the EC-50s of different cell lines treated with I-BET151; Supplementary Table S3: reports the 601 probes deregulated upon I-BET151 treatment, herein referred as the"I-BET151 signature;" Supplementary Table S4: reports the gene sets significantly enriched in the I-BET151 signature.
Table S3, S4 and S5 from Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer
Authors: O'Brien Neil , Conklin Dylan , Beckmann Richard , Luo Tong , Chau Kevin , Thomas Josh , Mc Nulty Ann , Marchal Christophe , Kalous Ondrej , von Euw Erika , Hurvitz Sara , Mockbee Colleen , Slamon Dennis J.
Published: April 2023

File containing three supplemental tables listing the mean tumor volumes and responses in the ER+/HER2-, HER2+/ER+ and TNBC xenografts
Supplementary Figure S5 from Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer
Authors: O'Brien Neil , Conklin Dylan , Beckmann Richard , Luo Tong , Chau Kevin , Thomas Josh , Mc Nulty Ann , Marchal Christophe , Kalous Ondrej , von Euw Erika , Hurvitz Sara , Mockbee Colleen , Slamon Dennis J.
Published: April 2023

Confirmation of G1 Cell Cycle arrest induced by abemaciclib, palbociclib and ribociclib
Supplementary Figure S4 from Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer
Authors: O'Brien Neil , Conklin Dylan , Beckmann Richard , Luo Tong , Chau Kevin , Thomas Josh , Mc Nulty Ann , Marchal Christophe , Kalous Ondrej , von Euw Erika , Hurvitz Sara , Mockbee Colleen , Slamon Dennis J.
Published: April 2023

Abemaciclib has activity in xenograft models of triple negative breast cancer with intact Rb-signaling